Introduction
============

German physicist Walter Bradford was the first who discovered X-rays and their properties in November 1885. Their properties attracted medical researchers to use them in the medical field ([@b1-etm-0-0-7056]). To increase the sensibility and specificity of the radiological techniques, contrast media have been introduced into the medical practice. They are currently being used worldwide to increase the visibility of the investigated structures. Contrast agents were first used in the beginning of the 20th century, but with high incidence of toxicity and poor results. In the 1950\'s the use of contrast agents increased due to new formulations that became available. In the 1970\'s non-ionic dimeric contrast agents were developed and today they play a major role in diagnosis, being the most used contrast agents in daily radiology practice ([@b2-etm-0-0-7056]).

Radiocontrast agents are typically iodine-, gadolinium- or barium-sulphate-based compounds and they can be administered orally or parenterally. Oral contrast agents are mostly used in the radiological diagnosis of the gastrointestinal tract. Contrast media for the bowel are classified as positive or negative, depending on whether the material is hyperattenuating or hypoattenuating relative to the walls of the gastrointestinal tract ([@b3-etm-0-0-7056]).

For the investigation of parenchymal organs and blood vessels, parenterally administered contrast media are used as iodinated contrast media (ICM) and gadolinium contrast media ([@b4-etm-0-0-7056]). Their administration is not totally safe, the adverse effects of the contrast media may be due to the type of administration, or to the type of agent used. The most common side effects after parenteral administration of contrast media are organ toxicity (with kidney being the most affected organ) ([@b5-etm-0-0-7056]) and hypersensitivity reactions ([@b6-etm-0-0-7056]).

The local side effect is represented by the contrast extravasation of the parenterally administrated agent, depending on the type of administration. As administration typically involves small volumes, it seldom leads to serious injuries. Non-communicative patients such as children or debilitated patients, multiple injections in the same vein, or friable vessels are considered to be risk factors ([@b7-etm-0-0-7056]).

The systemic side effects of the contrast media may occur early, usually in less than 20 min, or late (over 20 min), and the cause may be an anaphylactoid reaction or effects due to the osmolarity and chemotoxicity of the substance. The concentration, volume and rate of injection are also risk factors to be taken into consideration. Clinical reactions vary from minor, to intermediate, to severe and skin manifestations are the most frequent and sometimes the only manifestations that can be misinterpreted. The severe adverse reactions need an accurate diagnosis even if they are very rare because their evolution can be life-threatening ([@b8-etm-0-0-7056],[@b9-etm-0-0-7056]).

The aim of the study was to examine through a systematic analysis the studies published in the last 10 years regarding the incidence of immediate and delayed hypersensitivity reactions with skin manifestations, to identify the skin patterns that are characteristic in these types of reactions and to analyze the risk factors and comorbidities that can influence their appearance.

Materials and methods
=====================

### Search for studies

We performed multiple PubMed searches using all possible combinations between the following keywords: Contrast agents or contrast media and immediate, non-immediate, late, delayed, allergic reactions, allergic effects, skin lesions, adverse effects, skin hypersensitivity and side effects. After analyzing the results only studies relevant to the subject were included in this systematic analysis. For a more accurate search we also checked the references of excluded studies.

Inclusion criteria were: Large observational studies that analyze the incidence of immediate and/or delayed hypersensitivity reactions to different class of contrast media and/or their association with the comorbidities, written in English language in the last 10 years, i.e., from January, 2008 till January, 2018.

Exclusion criteria were: Articles written in languages other than English, studies published before January 2008, non-human studies, studies published only as abstracts, as reviews, meta-analyses, commentaries, editorials, and case-reports but only after a careful check of those references. After reading the abstract and entire article we excluded from the systematic review the articles that did not clearly present the manifestations observed in the immediate and delayed reactions to the contrast media and studies that presented the incidence of other types of adverse reactions, as the purpose of this review was the skin manifestations in contrast media adverse reactions ([Fig. 1](#f1-etm-0-0-7056){ref-type="fig"}).

Immediate hypersensitivity reactions to contrast media are defined as an allergic reaction that occurs within 30 min of contrast media administration. Delayed hypersensitivity reactions to contrast media are defined as reactions that appear between 1 h and 7 days after administration of the contrast agent ([@b6-etm-0-0-7056]).

Results
=======

### General

The initial research for the studies published in English between January 2008 and January 2018 yielded 929 articles. After excluding non-human studies and the reviews, meta-analyses, commentaries, editorials, and case-reports, 414 articles remained to be screened for their content by reading the abstract. In total, 51 full-articles were assessed for eligible studies to be included. Finally, 20 articles were included in the analysis. The selection procedure was carried out according to the inclusion and exclusion criteria and is presented in the PRISMA flow chart ([Fig. 1](#f1-etm-0-0-7056){ref-type="fig"}). We identified 11 studies that described immediate skin reactions to ICM, 9 studies that described immediate skin reactions to other contrast media, 6 studies that described delayed skin adverse reactions to ICM, and 3 studies that described delayed skin adverse reactions to other contrast media. Regarding the risk factors associated with the incidence of immediate and delayed allergic reactions from the studies included in the systematic review, 7 studies analyzed the risk factors associated with immediate allergic reactions to ICM and 4 studies analyzed the risk factors associated with immediate allergic reactions to other contrast agents. No study analyzed the risk factors associated with delayed allergic reactions.

### Incidence of immediate skin adverse reactions to ICM

The epidemiological studies published in the last 10 years that evaluate the incidence of immediate adverse reactions to ICM with skin manifestations identify a prevalence of immediate hypersensitivity reactions between 0.16 and 2.24%, from which the percentage of skin manifestation was between 33.33 and 87.7% ([Table I](#tI-etm-0-0-7056){ref-type="table"}) ([@b9-etm-0-0-7056]--[@b19-etm-0-0-7056]). Severe hypersensitivity reactions were between 0.010 and 0.024%, with anaphylaxis being the most frequent reaction ([Table I](#tI-etm-0-0-7056){ref-type="table"}) ([@b9-etm-0-0-7056],[@b10-etm-0-0-7056],[@b18-etm-0-0-7056]). Regarding the skin patterns observed in these cases, the most frequent were urticaria (between 30.77 and 83.78% of the cases with skin manifestations) ([@b10-etm-0-0-7056],[@b13-etm-0-0-7056],[@b15-etm-0-0-7056],[@b17-etm-0-0-7056]--[@b19-etm-0-0-7056]), rash (38.46--85.3%) ([@b9-etm-0-0-7056],[@b10-etm-0-0-7056],[@b13-etm-0-0-7056],[@b19-etm-0-0-7056]), itching sensation/pruritus (12.82--100%) ([@b10-etm-0-0-7056],[@b13-etm-0-0-7056]--[@b15-etm-0-0-7056],[@b17-etm-0-0-7056]--[@b19-etm-0-0-7056]), oedema (6.25--17.3%) ([@b12-etm-0-0-7056],[@b18-etm-0-0-7056],[@b19-etm-0-0-7056]), erythemas (36.54--100%) ([@b12-etm-0-0-7056],[@b14-etm-0-0-7056],[@b17-etm-0-0-7056]--[@b19-etm-0-0-7056]), angioedema (8%-13.51%) ([@b15-etm-0-0-7056],[@b17-etm-0-0-7056]), and angioneurotic oedema (3.84%) ([@b18-etm-0-0-7056]) ([Fig. 2](#f2-etm-0-0-7056){ref-type="fig"}).

Incidence of immediate skin adverse reactions to other contrast media. In [Table II](#tII-etm-0-0-7056){ref-type="table"} are presented the studies published in the last 10 years that evaluate the incidence of immediate adverse reactions to other contrast media except ICM with skin manifestations. We identified 6 studies that evaluated the immediate reactions to gadolinium-based contrast agents, 2 studies that evaluated the immediate reactions to sulfur hexafluoride microbubbles, a contrast agent used for contrast-enhanced ultrasound and 1 study that evaluated the immediate hypersensitivity reactions to sodium fluorescein.

Two studies investigated the immediate adverse reactions to sulfur hexafluoride microbubbles in pediatric patients. No immediate hypersensitivity effects were evident after the administration ([@b20-etm-0-0-7056],[@b21-etm-0-0-7056]).

Regarding the gadolinium contrast media the incidence of immediate hypersensitivity reactions was between 0.01 and 0.3%. The skin manifestations were observed in 75--100% of these reactions ([@b13-etm-0-0-7056],[@b22-etm-0-0-7056]--[@b27-etm-0-0-7056]). The most frequent skin manifestations associated with hypersensitivity reactions to gadolinium contrast agents were urticaria (63--91.1%) ([@b13-etm-0-0-7056],[@b22-etm-0-0-7056]--[@b24-etm-0-0-7056]), rash (20.4%) ([@b13-etm-0-0-7056],[@b22-etm-0-0-7056],[@b23-etm-0-0-7056]), pruritus (22.2%) ([@b23-etm-0-0-7056]), limited facial edema (6.17%) ([@b23-etm-0-0-7056]). Regarding the life-threatening severe hypersensitivity reactions only Kalaiselvan *et al* reported one case manifested by laryngospasm ([@b13-etm-0-0-7056]) ([Fig. 2](#f2-etm-0-0-7056){ref-type="fig"}).

Wallace *et al* evaluated the safety of fluorescein, a contrast agent utilized for confocal laser endomicroscopy. They determined an incidence of 1.4% of immediate side effects from which 28.12% had skin manifestations. The skin patterns observed were injection side erythema 88 and rash 12% (from the cases with skin effects) ([@b27-etm-0-0-7056]).

### Incidence of delayed skin adverse reactions to ICM

The delayed hypersensitivity reactions were also reported in the studies published in the last 10 years that investigated the safety of ICM ([Table III](#tIII-etm-0-0-7056){ref-type="table"}). A prevalence of 0.42 and 14.3% was observed, from which the incidence of skin manifestations were between 43.05 and 100% ([@b11-etm-0-0-7056],[@b14-etm-0-0-7056],[@b17-etm-0-0-7056]--[@b19-etm-0-0-7056],[@b28-etm-0-0-7056]). The most frequent skin pattern was angioedema (between 11.1 and 43.7%) ([@b13-etm-0-0-7056],[@b16-etm-0-0-7056]), itching/pruritus (18.7--55.6%) ([@b10-etm-0-0-7056],[@b13-etm-0-0-7056],[@b16-etm-0-0-7056]--[@b18-etm-0-0-7056],[@b27-etm-0-0-7056]) and maculopapular exanthema (33.3--37.5%) ([@b14-etm-0-0-7056],[@b17-etm-0-0-7056]). Other reactions with low incidence were erythema, rash, urticarial, and oedema ([@b11-etm-0-0-7056],[@b14-etm-0-0-7056],[@b17-etm-0-0-7056]--[@b19-etm-0-0-7056],[@b28-etm-0-0-7056]) ([Fig. 2](#f2-etm-0-0-7056){ref-type="fig"}).

In a study by Häussler 3 cases (0.03%) of severe delayed hypersensitivity reactions were reported: i) One 59-year-old female that experienced hypersensitivity, pruritus, urticarial, increased blood pressure, vomiting, swelling of the face, eyelid edema, facial edema, diarrhea and tachycardia; ii) one 53-year-old female that presented hypersensitivity, swelling of the face, erythema, and skin irritation and; iii) one 79-year-old male that presented hypersensitivity, rash, pruritus, dermatitis, and erythema. All 3 cases needed hospitalization ([@b18-etm-0-0-7056]).

### Incidence of delayed skin adverse reactions to other contrast media

Delayed skin reactions to other contrast media except ICM were investigated in only 3 studies published in the last 10 years ([Table IV](#tIV-etm-0-0-7056){ref-type="table"}). Two studies evaluated the safety of sulfur hexafluoride microbubbles in pediatric population and reported no delayed adverse effects ([@b20-etm-0-0-7056],[@b21-etm-0-0-7056]). Power *et al* reported an incidence of 0.05% delayed sensitivity reactions to gadolinium-based contrast agents with skin lesions. The symptoms observed were urticaria (66%), rash (33%) and pruritus (6.6%). Delayed reactions occurred on the same day in 46% of cases, on the following day in 20% of cases and in 33% of cases the moment of manifestation was uncertain ([@b23-etm-0-0-7056]) ([Fig. 2](#f2-etm-0-0-7056){ref-type="fig"}).

### Risk factors associated with immediate allergic reactions to ICM

Several risk factors were associated with the appearance of immediate hypersensitivity reactions to ICM. We identified 7 studies there of ([Table V](#tV-etm-0-0-7056){ref-type="table"}). The female sex was associated with increased risk for immediate allergic reactions to ICM between 51.44 and 65.95% ([@b9-etm-0-0-7056],[@b10-etm-0-0-7056],[@b14-etm-0-0-7056],[@b15-etm-0-0-7056],[@b17-etm-0-0-7056],[@b18-etm-0-0-7056]). Other risk factors identified included history of previous reactions to ICM (1.2--11.6%) ([@b9-etm-0-0-7056],[@b12-etm-0-0-7056]--[@b15-etm-0-0-7056],[@b17-etm-0-0-7056]), atopy (14.3%) ([@b8-etm-0-0-7056]), asthma (2.1--12.7%) ([@b9-etm-0-0-7056],[@b14-etm-0-0-7056],[@b15-etm-0-0-7056],[@b17-etm-0-0-7056]), drug allergy (3.6--25%) ([@b9-etm-0-0-7056],[@b14-etm-0-0-7056],[@b15-etm-0-0-7056],[@b17-etm-0-0-7056]), and allergic rhinitis (1.5--4%) ([@b14-etm-0-0-7056],[@b15-etm-0-0-7056],[@b17-etm-0-0-7056]).

The study of Morales-Cabeza *et al* associated the immediate allergic reactions to concomitant treatment with β-blockers (7.9%) or angiotensin-converting enzyme inhibitors (ACEI) (13.2%) ([@b9-etm-0-0-7056]).

### Risk factors associated with immediate allergic reactions to other contrast media

Being female was associated with gadolinium-based contrast agents and immediate adverse reactions in 65.2--81.25% of cases ([@b22-etm-0-0-7056]--[@b24-etm-0-0-7056],[@b26-etm-0-0-7056]). Immediate adverse reactions to other contrast media were associated with previous reaction to gadolinium contrast media (7.31--8.5%) ([@b23-etm-0-0-7056],[@b26-etm-0-0-7056]), asthma (2.9--11%) ([@b23-etm-0-0-7056],[@b24-etm-0-0-7056],[@b26-etm-0-0-7056]), drug hypersensitivity (2%) ([@b24-etm-0-0-7056]), allergic rhinitis (2.9%) ([@b24-etm-0-0-7056]), and chronic urticaria (2%) ([@b24-etm-0-0-7056]) ([Table VI](#tVI-etm-0-0-7056){ref-type="table"}).

Discussion
==========

In our systematic literature search the incidence of overall skin immediate reactions to ICM had an incidence between 1.15 and 0.12%, depending on the cohort analyzed in the studies. Goksel *et al* ([@b17-etm-0-0-7056]) analyzed only a cohort of 1,131 patients and observed an incidence of 1.15% of immediate reactions with skin manifestations in comparison with Ho *et al* ([@b15-etm-0-0-7056]) who analyzed a cohort of 29,962 patients and determined an incidence of 0.12%. The percentage of cutaneous manifestations in the cohort that experienced immediate hypersensitivity reactions was between 33.33 and 87.7%, with most of the studies reporting percentages above 50%. The most frequent symptoms observed were urticaria, rash, itching and erythemas. Severe immediate adverse reactions, anaphylactic manifestations being the most frequent, were also identified. Those results are in accordance with the older studies, which reported a prevalence of 3.8 and 12.7% of mild immediate CM reactions after using an ionic-iodinated CM and between 0.7 and 3.1% for non-ionic-iodinated CM ([@b29-etm-0-0-7056]--[@b32-etm-0-0-7056]). Most of the studies discussed in the present systematic analysis reported results after exposure to non-ionic ICM.

The mechanism of CM-induced allergic reaction is unclear and multifactorial and it is considered that more mechanisms are involved. The main mechanism considered is type-I hypersensitivity mechanism. Other proposed mechanisms are associated with histamine release from mast cells and basophils or activation of the complement system. Studies have shown that osmolarity or chemical structure of ICM can act directly on the cells and determine direct membrane effects that lead to these types of reactions ([@b33-etm-0-0-7056]). Previous findings showed that some ICM activate one of the true hypersensitivity pathways. The lower rate of adverse reactions to gadolinium-based contrast media is probably due to limited data available ([@b34-etm-0-0-7056]). Therefore, most immediate adverse reactions to contrast media probably occur through different pathways, supported by high level of histamine observed in the serum of patients with this type of reactions ([@b33-etm-0-0-7056]).

Non-iodinated contrast agents have a safer profile compared with ICM, the incidence of immediate adverse reactions being very low in gadolinium-based contrast agents and other agents used for contrast-enhanced ultrasound (CEUS). Previous studies showed that gadolinium-based contrast agents determine mild, moderate and severe immediate adverse reactions with an incidence of 0.07 and 3.1% ([@b35-etm-0-0-7056]--[@b37-etm-0-0-7056]), which is in accordance with our findings. The incidence of immediate adverse reactions was identified as 0.01 and 1.3%, from which the skin manifestations were presented in 75 and 100% of cases. The most frequent skin manifestations were urticaria, rashes, pruritus and limited facial edema. Regarding other contrast agents, the ones used for CEUS are considered a safer alternative, especially in pediatric population where CT and MRI investigations present numerous disadvantages with regard to sedation or general anesthesia. The incidence of immediate adverse reactions to CEUS agents was very low, around 0.0086% ([@b38-etm-0-0-7056]). In our systematic analysis, we identified 2 studies that reported no immediate adverse reaction to sulfur hexafluoride microbubbles used as CM for CEUS in pediatric population.

In the studies analyzed in our systematic analysis the incidence of delayed reactions to ICM was between 10.1 and 0.03%. The higher incidence observed can also be determined because of the low cohort investigated of only 258 patients compared with the study where the lowest incidence was observed, which analyzed 55,286 subjects. Older studies showed an incidence of delayed reactions to ICM of 2 and 5% ([@b39-etm-0-0-7056]--[@b42-etm-0-0-7056]). In the studies we analyzed the main adverse reactions due to delayed hypersensitivity phenomena were cutaneous manifestations that were present between 70.27 and 100% of the cases analyzed. The skin manifestations in the mild and moderate reactions were rash, urticaria, pruritus or erythema and angioedema. The severe reactions are very rare but life threatening, being a significant problem for both the patients and physicians involved. Between the skin patterns observed in the severe delayed reactions there were reported multiform erythema ([@b43-etm-0-0-7056]), cutaneous vasculitis ([@b44-etm-0-0-7056]), fixed drug eruption ([@b45-etm-0-0-7056]), Stevens-Johnson syndrome ([@b46-etm-0-0-7056]), and toxic epidermal necrolysis ([@b47-etm-0-0-7056]). We identified only one study that reported 3 cases of severe delayed reactions (0.03%) from 9,515 patients exposed to contrast agents ([@b18-etm-0-0-7056]). The skin manifestations observed in these patients were pruritus, urticarial, swelling of the face, eyelid edema, facial edema, rash and erythema ([@b18-etm-0-0-7056]).

The mechanism of appearance of these delayed reactions is mediated via T cells. This mechanism is supported by the studies that showed the presence of dermal infiltrates of T cells in affected skin and at positive skin test sites, the reappearance of the eruption after provocation testing and by the ability of CM to stimulate the proliferation of peripheral T cells from patients with CM-induced skin eruptions ([@b48-etm-0-0-7056]).

The delayed sensitivity reactions to other contrast media except ICM are rarely reported, also because these products are on the market for a short period ([@b49-etm-0-0-7056]). We identified only one study that reported an incidence of 0.05% delayed sensitivity reactions and the skin manifestations observed were urticarial, rash and pruritus ([@b23-etm-0-0-7056]). No severe reactions were reported ([@b23-etm-0-0-7056]).

The hypersensitivity reactions to ICM are associated with certain associated factors that may be risk factors and a correct investigation of the patient before the use of a certain contrast agent can be beneficial for decreasing the risk of its manifestation. History of allergy, history of previous reactions to CM, age less than 50 years, female sex, history of cardiac disease, and concomitant treatment with other drugs such as β-blockers or ACEI were identified as risk factors, which is in accordance with older studies ([@b50-etm-0-0-7056],[@b51-etm-0-0-7056]). History of asthma was associated with severe reactions, thus in these patients other alternatives could be suggested.

Regarding the risk factors for developing immediate adverse reactions to gadolinium-based CM, the studies showed a similar pattern as those that appear after exposure to ICM, female gender being a predisposing factor, a percentage between 65.2 and 81.7% from those that developed immediate hypersensitivity reactions to gadolinium-based contrast agents were women, findings that are in concordance with the older literature ([@b26-etm-0-0-7056],[@b52-etm-0-0-7056]). These differences are not well explained, but animal studies suggested that specific sex hormones may be involved in the increased incidence in females ([@b53-etm-0-0-7056]). History of allergy and history of previous reaction to CM is an important determinant factor. In the studies analyzed, age and concomitant treatment were not found to be risk factors, even if other studies reported them as such ([@b54-etm-0-0-7056]).

In conclusion, contrast agents are extensively used at present for a large range of imagistic investigations and their utilization is not totally safe. Irrespective of the class of contrast agents to which they belong, immediate or delayed adverse reactions could appear, ICM presenting a higher incidence compared with new agents as gadolinium-based contrast agents or others utilized for CEUS. Skin manifestations are the most frequent manifestations in all the type of allergic reactions and a precise diagnosis can be very helpful in practice. Several risk factors were associated with the appearance of immediate hypersensitivity reactions to contrast media. An accurate anamnesis of the patients and a correctly conducted pretreatment can limit the incidence and the severity of the adverse reactions and also can avoid the occurrence of life threatening reactions.

This study is part of the PhD theses of Andrei Mihai Iordache from the University of Medicine and Pharmacy of Craiova, Craiova, Romania.
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###### 

Studies that evaluated the incidence of immediate skin adverse reactions to iodinated contrast media.

  Studies, year                  Study type/samples                                                                   Iodinated contrast media                                                                                                                                     Overall skin reactions (%)         Skin reactions from total immediate adverse reactions (%)   Severe reactions (%)                 Refs.
  ------------------------------ ------------------------------------------------------------------------------------ ------------------------------------------------------------------------------------------------------------------------------------------------------------ ---------------------------------- ----------------------------------------------------------- ------------------------------------ -----------------------
  Morales-Cabeza *et al*, 2017   Prospective study/161,319 procedures                                                 Iopamidol, Ioversol, Iomeprol                                                                                                                                0.18                               87.7                                                        0.010                                ([@b9-etm-0-0-7056])
  Kim *et al*, 2017              Retrospective study/286,087 procedures                                               Iobitridol, Iohexol, Iopamidol, Iopromide                                                                                                                    0.69                               Not specify                                                 0.024 (anaphylaxis)                  ([@b10-etm-0-0-7056])
  Zhang *et al*, 2014            Prospective study/20,185 subjects                                                    Iodixanol                                                                                                                                                    0.19                               33.33                                                       0.009                                ([@b11-etm-0-0-7056])
  García *et al*, 2014           Retrospective study/Iopromide investigation 72,887; Iomeprol investigations 37,154   Iopromide, Iomeprol                                                                                                                                          Iopromide (0.27) Iomeprol (0.19)   Iopromide (56.7) Iomeprol (41.1)                            Iopromide (0.014) Iomeprol (0.045)   ([@b12-etm-0-0-7056])
  Kalaiselvan *et al*, 2014      Retrospective study/59,915 subjects                                                  Diatrizoate, Iothalmate, Ioxaglate Iobitridol, Iodixanol, Iohexol Iomeprol, Ioversol, Iopromide Iopamidol, Iodized oil                                       0.47                               Not specify                                                 0.07                                 ([@b13-etm-0-0-7056])
  Pradubpongsa *et al*, 2013     Retrospective study/55,286 subjects                                                  Low osmolarity CM (non-ionic iodinated monomer), high osmolarity CM (ionic iodinated monomer and dimer), and iso-osmolarity CM (non-ionic iodinated dimer)   0.83                               74.2                                                        0.024                                ([@b14-etm-0-0-7056])
  Ho *et al*, 2012               Prospective study/29,962 subjects                                                    Iopromide                                                                                                                                                    0.12                               78.72                                                       0.003                                ([@b15-etm-0-0-7056])
  Mitchell *et al*, 2011         Prospective study/633 patients                                                       Iopamidol                                                                                                                                                    0.47                               60                                                          0                                    ([@b16-etm-0-0-7056])
  Goksel *et al*, 2011           Retrospective study/1,131 subjects                                                   Iohexol, Iomeprol, Ioxilan, Iopamidol, Iodixanol, Iobitridol                                                                                                 1.15                               Not specify                                                 --                                   ([@b17-etm-0-0-7056])
  Häussler, 2010                 Retrospective study/9,515 patients                                                   Iodixanol                                                                                                                                                    0.31                               Not specify                                                 0.02                                 ([@b18-etm-0-0-7056])
  Lapi *et al*, 2008             Prospective study/1,514 patients                                                     Iopromide, Iodixanol, Iomeprol, Iobitridol                                                                                                                   1.05                               47                                                          0.06                                 ([@b19-etm-0-0-7056])

###### 

Studies that evaluated the incidence of immediate skin adverse reactions to other contrast media.

  Studies, year               Study type/samples                                                                                            Other contrast media                                                                                                                                                 Overall skin reactions (%)   Skin reactions from total immediate adverse reactions (%)   Severe reactions (%)   Refs.
  --------------------------- ------------------------------------------------------------------------------------------------------------- -------------------------------------------------------------------------------------------------------------------------------------------------------------------- ---------------------------- ----------------------------------------------------------- ---------------------- -------------------------
  Kalaiselvan *et al*, 2014   Retrospective study/59,915 patients                                                                           Gadopentetate, Gadoterate, Gadolinium, Gadodiamide,                                                                                                                  0.01                         100                                                         0.005                  ([@b13-etm-0-0-7056])
  Torres *et al*, 2017        Retrospective study/173 pediatric patients that underwent 287 CEUS                                            Sulfur hexafluoride microbubbles                                                                                                                                     0                            0                                                           0                      ([@b20-etm-0-0-7056])
  Yusuf *et al*, 2017         Retrospective study/305 pediatric patients that underwent CEUS                                                Sulfur hexafluoride microbubbles                                                                                                                                     0                            0                                                           0                      ([@b21-etm-0-0-7056])
  Granata *et al*, 2016       Retrospective study/10,608 Caucasian patients                                                                 Gd-BOPTA (Gadobenate dimeglumine) Gd-EOB-DTPA (gadoxetic acid disodium) Gd-DOTA (gadoterate meglumine) Gd-BT-DO3A (gadobutrol) Gd-DTPA (gadopentetate dimeglumine)   0.23                         75                                                                                 ([@b22-etm-0-0-7056])
  Power *et al*, 2016         Observational study/30,373 gadobutrol investigations                                                          Gadobutrol                                                                                                                                                           0.27                         100                                                         0.003                  ([@b23-etm-0-0-7056])
  Jung *et al*, 2012          Retrospective study between/141,623 administrations                                                           Gadoteric acid, Gadobutrol, Gadopentetate, Dimeglumine, Gadobenate, Dimeglumine, Gadoxetic acid, Gadodiamide,                                                        0.076                        96.42                                                                              ([@b24-etm-0-0-7056])
  Emond *et al*, 2011         Observational study/104 neonates and infants (\<18 months)                                                    Gadoteric acid                                                                                                                                                       0                            0                                                           0                      ([@b25-etm-0-0-7056])
  Prince *et al*, 2011        Retrospective study/158,796 gadolinium-based contrast agent enhanced examination                              Gadodiamide, Gadopentetate, Dimeglumine, Gadoteridol, Gadobenate Dimeglumine, Gadoxetate                                                                             0.06                         100                                                         0.002                    ([@b26-etm-0-0-7056])
  Wallace *et al*, 2010       A cross-sectional survey of 16 International Academic Medical Centres/2,272 gastrointestinal CLE procedures   10% Sodium fluorescein                                                                                                                                               0.39                         28.12                                                       0                      ([@b27-etm-0-0-7056])

CEUS, contrast-enhanced ultrasound.

###### 

Studies that evaluated the incidence of delayed skin adverse reactions to iodinated contrast media.

  Studies, year                Study type/samples                    Iodinated contrast media                                                                                                                                     Overall reactions (%)   Severe reactions (%)   Skin reactions from total delayed adverse reactions (%)   Refs.
  ---------------------------- ------------------------------------- ------------------------------------------------------------------------------------------------------------------------------------------------------------ ----------------------- ---------------------- --------------------------------------------------------- -----------------------
  Goksel *et al*, 2011         Retrospective study/1,131 subjects    Iohexol, Iomeprol, Ioxilan, Iopamidol, Iodixanol, Iobitridol                                                                                                 1.41                    100                    0                                                         ([@b17-etm-0-0-7056])
  Pradubpongsa *et al*, 2013   Retrospective study/55,286 subjects   Low osmolarity CM (non-ionic iodinated monomer), high osmolarity CM (ionic iodinated monomer and dimer), and iso-osmolarity CM (non-ionic iodinated dimer)   0.03                    100                    0                                                         ([@b14-etm-0-0-7056])
  Zhang *et al*, 2014          Prospective study/20,185 subjects     Iodixanol                                                                                                                                                    0.68                    100                    0                                                         ([@b11-etm-0-0-7056])
  Häussler *et al*, 2010       Retrospective study/9,515 patients    Iodixanol                                                                                                                                                    0.42                    100                    0.03                                                      ([@b18-etm-0-0-7056])
  Loh *et al*, 2010            Prospective study/258 patients        Iohexol                                                                                                                                                      10.1                    70.27                  0                                                         ([@b28-etm-0-0-7056])
  Lapi *et al*, 2008           Prospective study/1,514 patients      Iopromide, Iodixanol, Iomeprol, Iobitridol                                                                                                                   4.09                    43.05                  0                                                         ([@b19-etm-0-0-7056])

###### 

Studies that evaluated the incidence of delayed skin adverse reactions to other contrast media.

  Studies, year          Study type/samples                                                   Iodinated contrast media           Overall reactions (%)   Skin reactions from total delayed adverse reactions (%)   Severe reactions (%)   Refs.
  ---------------------- -------------------------------------------------------------------- ---------------------------------- ----------------------- --------------------------------------------------------- ---------------------- -----------------------
  Torres *et al*, 2017   Retrospective study/173 pediatric patients that underwent 287 CEUS   Sulfur hexafluoride microbubbles   0                       0                                                         0                      ([@b20-etm-0-0-7056])
  Yusuf *et al*, 2017    Retrospective study/305 pediatric patients that underwent CEUS       Sulfur hexafluoride microbubbles   0                       0                                                         0                      ([@b21-etm-0-0-7056])
  Power *et al*, 2016    Observational study/30,373 gadobutrol investigations                 Gadobutrol                         0.05                    100                                                       0                      ([@b23-etm-0-0-7056])

CEUS, contrast-enhanced ultrasound.

###### 

Studies that evaluated the risk factors associated with immediate allergic reactions to iodinated contrast media.

  Studies, year                  Study type/samples                                                                  History of allergy                                                                                                                           History of previous reaction to CM   Age (years)                                  Concomitant treatment            Sex                History of cardiac disease   Refs.
  ------------------------------ ----------------------------------------------------------------------------------- -------------------------------------------------------------------------------------------------------------------------------------------- ------------------------------------ -------------------------------------------- -------------------------------- ------------------ ---------------------------- -----------------------
  Morales-Cabeza *et al*, 2017   Prospective study/161,319 procedures                                                Atopy (14,3%) Asthma (5,9%) Drug allergy (13,2%)                                                                                             7%                                   --                                           β-blockers (7,9%) ACEI (13,2%)   Female (52.3%)     --                           ([@b9-etm-0-0-7056])
  Kim *et al*, 2017              Retrospective study/286,087 procedures                                              --                                                                                                                                           --                                   20--50 (34.4%)                               --                               Females (51.44%)   --                           ([@b10-etm-0-0-7056])
  Goksel *et al*, 2011           Retrospective study/1,131 subjects                                                  Drug allergies (3.6%) Asthma (4.4%) Allergic rhinitis (1.5%) Chronic urticaria/Angioedema (1%) Contact dermatitis (1%) Food allergy (0.4%)   2.92%                                                                                                              Females (55.7%)    33.2%                        ([@b17-etm-0-0-7056])
  Pradubpongsa *et al*, 2013     Retrospective study/55,286 subjects                                                 Drug allergy (13.1%) Seafood allergy (7.1%) Allergic rhinitis (2.8%) Asthma (2.1%) Chronic urticaria (0.9%)                                  11.6%                                --                                           --                               Females (58.7%)    27.6%                        ([@b14-etm-0-0-7056])
  García *et al*, 2014           Retrospective study/Iopromide investigation 72,887 Iomeprol investigations 37,154   Iopromide (6.5%) Iomeprol (16.3%) -                                                                                                          Iopromide (4%) Iomeprol (1.2%) -     --                                           --                               --                 --                           ([@b12-etm-0-0-7056])
  Häussler *et al*, 2010         Retrospective study/9,515 patients                                                  --                                                                                                                                           --                                   18--50 (0.66%) compared to only 0.22% \>51   --                               Females (65.45%)   --                           ([@b18-etm-0-0-7056])
  Ho *et al*, 2012               Prospective study/29,962 subjects                                                   Asthma (12.7%) Allergy to other substances (25%) Allergic rhinitis (4%)                                                                      4%                                   --                                           --                               Females (65.95%)   --                           ([@b15-etm-0-0-7056])

###### 

Risk factors associated with immediate allergic reactions to other contrast media than ICM.

  Studies, year           Study type/samples                                                                 History of allergy                                                                         History of previous reaction to CM                                                            Age (years)   Concomitant treatment   Sex                History of cardiac disease   Refs.
  ----------------------- ---------------------------------------------------------------------------------- ------------------------------------------------------------------------------------------ --------------------------------------------------------------------------------------------- ------------- ----------------------- ------------------ ---------------------------- -----------------------
  Granata *et al*, 2016   Retrospective study/10,608 Caucasian patients gadolinium-based CM                  --                                                                                         --                                                                                            --            --                      Females (81.25%)   --                           ([@b22-etm-0-0-7056])
  Power *et al*, 2016     Observational study/30,373 gadobutrol investigations                               Asthma (11%)                                                                               7.31% previous reaction to gadolinium-based contrast agents 10.97% previous reaction to ICM   --            --                      Females (81.7%)    --                           ([@b23-etm-0-0-7056])
  Jung *et al*, 2012      Retrospective study between/141,623 administrations gadolinium-based CM            Asthma (2.9%) Allergic rhinitis (2.9%) Drug hypersensitivity (2%) Chronic urticaria (2%)   --                                                                                            --            --                      Females (65.2%)    --                           ([@b24-etm-0-0-7056])
  Prince *et al*, 2011    Retrospective study/158,796 gadolinium-based contrast agent enhanced examination   Asthma (8.5%) Previous allergic event (40.4%)                                              8.5% previous reaction to gadolinium-based contrast agents                                    --            --                      Females (76,6%)    --                           ([@b26-etm-0-0-7056])

ICM, iodinated contrast media.
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